Molecular Weight(MW): 503.64
XL888 is an ATP-competitive inhibitor of HSP90 with IC50 of 24 nM. Phase 1.
1 Customer Review
B, XL888 (1 mmol/L, 144 hours) is effective at blocking the growth and survival of vemurafenib-resistant melanoma cell lines grown as 3D collagen-implanted spheroids. Staining shows cell viability, in which green corresponds to live cells and red: dead cells. Magnification×4.
Clin Cancer Res, 2012, 18(9):2502-2514.. XL888 purchased from Selleck.
Purity & Quality Control
Choose Selective HSP (e.g. HSP90) Inhibitors
|Description||XL888 is an ATP-competitive inhibitor of HSP90 with IC50 of 24 nM. Phase 1.|
XL888 induces HER2 degradation in NCI-N87 cells with IC50 of 56 nM. XL888 inhibits the proliferation of HER2 over-expressed NCI-N87, HER2 over-expressed BT-474, HER2 over-expressed MDA-MB-453, MET mutated MKN45, B-Raf mutated Colo-205, B-Raf mutated SK-MEL-28, EGFR mutated HN5, EGFR mutated NCI-H1975, PI3K mutated MCF7, and K-Ras mutated A549 with IC50 of 21.8, 0.1, 16.0, 45.5, 11.6, 0.3, 5.5, 0.7, 4.1 and 4.3 nM.  XL888 leads to dose-dependent decreases in the growth of vemurafenib-naive and vemurafenib-resistant melanoma cell lines and melanoma cell lines with intrinsic resistance with IC50 of all around 0.1 μM. The growth inhibitory effects of XL888 are associated with induction of either a G1-phase cell-cycle arrest (WM164, M229, M229R, M249, M249R, 1205Lu, and WM39 cell lines) or a G2-M phase cell-cycle arrest (WM164R, 1205LuR, and RPMI 7951 cell lines). XL888 (300 nmol) induces high levels ( > 66%) of apoptosis, and loss of mitochondrial membrane potential (TMRM) in these cell lines. The cytotoxic effects of XL888 are durable with no signs of colony formation observed in any of the cell lines even cultured up to 4 weeks. XL888 treatment (300 nM, 48 hours) leads to the degradation of IGF1R, PDGFRβ, ARAF, CRAF, and cyclin D1 and the inhibition of AKT, ERK, and S6 signaling in all of the cell lines with acquired BRAF inhibitor resistance. treatment of cell lines that are naive, intrinsically resistant, and with acquired vemurafenib resistance. Treatment with XL888 (300 nM) leads to robust time-dependent increases in the expression of HSP70 isoform 1. XL888 (48 hours, 300 nM) treatment increases the expression of BIM-EL, BIM-L, and BIM-S expression in the M229R, 1205LuR, RPMI7951, and WM39 cell lines, induces expression of BIM-L and BIM-S in the WM164R cell line, and BIM-EL in the M249R cell line. 
|In vivo||XL888 (100 mg/kg) significantly induces the regression of, or growth inhibition (50%) of established M229R and 1205LuR xenografts in SCID mice. 15 days of XL888 treatment showes a robust (8.6-fold) increase in intratumoral HSP70 expression compared with controls. XL888 treatment is noted to be proapoptotic in vivo and leads to increased TUNEL staining in M229R xenografts associated with increased expression of BIM and decreased expression of Mcl-1. |
|In vitro||DMSO||100 mg/mL (198.55 mM)|
|In vivo||Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03095781||Recruiting||Adenocarcinoma of the Gastroesophageal Junction|Colorectal Adenocarcinoma|Metastatic Pancreatic Adenocarcinoma|Non-Resectable Cholangiocarcinoma|Non-Resectable Hepatocellular Carcinoma|Recurrent Cholangiocarcinoma|Recurrent Colorectal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Hepatocellular Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Small Intestinal Carcinoma|Small Intestinal Adenocarcinoma|Stage III Colorectal Cancer|Stage III Gastric Cancer|Stage III Hepatocellular Carcinoma|Stage III Pancreatic Cancer|Stage III Small Intestinal Cancer|Stage IIIA Colorectal Cancer|Stage IIIA Gastric Cancer|Stage IIIA Hepatocellular Carcinoma|Stage IIIA Small Intestinal Cancer|Stage IIIB Colorectal Cancer|Stage IIIB Gastric Cancer|Stage IIIB Hepatocellular Carcinoma|Stage IIIB Small Intestinal Cancer|Stage IIIC Gastric Cancer|Stage IV Colorectal Cancer|Stage IV Gastric Cancer|Stage IV Hepatocellular Carcinoma|Stage IV Pancreatic Cancer|Stage IV Small Intestinal Cancer|Stage IVA Colorectal Cancer|Stage IVA Hepatocellular Carcinoma|Stage IVA Pancreatic Cancer|Stage IVB Colorectal Cancer|Stage IVB Hepatocellular Carcinoma|Stage IVB Pancreatic Cancer|Unresectable Pancreatic Carcinoma|Unresectable Small Intestinal Carcinoma||Emory University|Merck Sharp & Dohme Corp.|Exelixis||June 28 2017||Phase 1|
|NCT02721459||Recruiting||Melanoma|Skin Cancer||H. Lee Moffitt Cancer Center and Research Institute|Exelixis|Genentech Inc.||August 11 2016||Phase 1|
|NCT01657591||Active not recruiting||Melanoma||H. Lee Moffitt Cancer Center and Research Institute|Exelixis||July 27 2012||Phase 1|
|NCT00796484||Terminated||Cancer||Exelixis||November 2008||Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.